{"id":"slamf7","name":"SLAMF7 (CS1)","symbol":"SLAMF7","route":"/targets/slamf7/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21394","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000026751","uniprot":"https://www.uniprot.org/uniprotkb/Q9NQ25/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q9NQ25","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3559386","open-targets":"https://platform.opentargets.org/target/ENSG00000026751","civic":"https://civicdb.org/genes/57823/summary","oncokb":"https://www.oncokb.org/gene/SLAMF7","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLAMF7","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=SLAMF7","depmap":"https://depmap.org/portal/gene/SLAMF7?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000026751-SLAMF7","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/57823","omim":"https://www.omim.org/entry/606625"}],"products":[{"id":"elotuzumab","name":"Elotuzumab","status":"approved","modality":"Anti-SLAMF7 monoclonal antibody","route":"/drugs/elotuzumab/"}],"trials":[{"id":"nct06208150","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","nct":"NCT06208150","phase":"3","status":"active"},{"id":"nct05730036","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","nct":"NCT05730036","phase":"3","status":"recruiting"},{"id":"nct06152575","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","nct":"NCT06152575","phase":"3","status":"recruiting"},{"id":"nct06158841","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","nct":"NCT06158841","phase":"3","status":"active"},{"id":"nct03989414","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","nct":"NCT03989414","phase":"1/2","status":"active"}],"pathways":[],"companies":["bms"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}